Adverse events · Patients with acute pouchitis
It is very uncertain whether metronidazole changes adverse events compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical remission · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical remission compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical improvement · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical improvement compared with budesonide enema (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No episodes of acute pouchitis · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic cure with all exclusions treated as failures · patients with Clostridium difficile‐associated diarrhoea in adults
Metronidazole probably leads to lower symptomatic cure with all exclusions treated as failures compared with vancomycin (moderate certainty).
1 finding from 1 review
Bacteriologic Cure · patients with Clostridium difficile‐associated diarrhoea in adults
It is very uncertain whether metronidazole changes bacteriologic cure compared with vancomycin (very low certainty).
1 finding from 1 review
Cure (combined symptomatic and bacteriologic cure) ‐ mild disease · patients with Clostridium difficile‐associated diarrhoea in adults
It is very uncertain whether metronidazole changes cure (combined symptomatic and bacteriologic cure) ‐ mild disease compared with vancomycin (very low certainty).
1 finding from 1 review
Cure (combined symptomatic and bacteriologic cure) ‐ severe disease · patients with Clostridium difficile‐associated diarrhoea in adults
It is very uncertain whether metronidazole changes cure (combined symptomatic and bacteriologic cure) ‐ severe disease compared with vancomycin (very low certainty).
1 finding from 1 review
Malodour (smell score measured on a scale of 0 to 3 with higher scores indicating a more offensive smell) · treating malignant wounds
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Very low
Adverse effects · treating malignant wounds
1 finding from 1 review
no estimate extracted
1 study · 6 participants
GRADE not reported
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Metronidazole showed no clear difference in proportion of participants with adverse event compared with placebo (high certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Metronidazole probably leads to higher physician‐assessed improvement in rosacea severity compared with placebo (moderate certainty).
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission · Participants with rosacea
Metronidazole probably leads to lower duration of remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical attachment level (CAL) · Adults with periodontitis (chronic and aggressive)
Metronidazole + SRP showed no clear difference in clinical attachment level (CAL) compared with amoxicillin + metronidazole + SRP; GRADE not reported.
2 findings from 1 review